MedTrace Logo

Probiotics and Multi-Drug Resistant Urinary Tract Infection

NCT03644966 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-04-12

No results posted yet for this study

Summary

This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.

Conditions

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium infantis

Probiotics

OTHER

Placebo

Sugar pill manufactured to mimic probiotic tablet

DRUG

Antibiotics

Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • Ochsner Health System

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-05
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03644966 on ClinicalTrials.gov